Contact | Print version | PDF version | Send article | RSS feed

DelSiTech signs License Agreement with Bayer Innovation

22 Jan 2007 - DelSiTech Ltd and Bayer Innovation GmbH announced that they entered into a license agreement. The agreement enables Bayer the exclusive rights to use the unique and proprietary DelSiTech ® drug delivery technology for fiber applications in the fields of wound care and certain other applications.
 
Under the terms of the agreement DelSiTech will receive a signing fee, milestone payments and further royalties for future sales of the products using the DelSiTech technology. The agreement contains also an option for further collaboration.
 
The DelSiTech ® drug delivery technology is a result of a cross-disciplinary project including researchers from the University of Turku and the Swedish-speaking University in Turku called Åbo Akademi. After the transfer of the technology, DelSiTech has started the industrialization process of the same. According to the compnay, it has been possible to encapsulate and controllably release extremely labile viruses and proteins to clinically useful applications by combining the in depth know-how and IPR of silica chemistry with the newest nano technology.